253 related articles for article (PubMed ID: 24477657)
21. Extension of microRNA expression pattern associated with high-risk neuroblastoma.
Bienertova-Vasku J; Mazanek P; Hezova R; Curdova A; Nekvindova J; Kren L; Sterba J; Slaby O
Tumour Biol; 2013 Aug; 34(4):2315-9. PubMed ID: 23784455
[TBL] [Abstract][Full Text] [Related]
22. Integrated Analysis of Thyroid Cancer Public Datasets Reveals Role of Post-Transcriptional Regulation on Tumor Progression by Targeting of Immune System Mediators.
Geraldo MV; Kimura ET
PLoS One; 2015; 10(11):e0141726. PubMed ID: 26536459
[TBL] [Abstract][Full Text] [Related]
23. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
Rachagani S; Macha MA; Heimann N; Seshacharyulu P; Haridas D; Chugh S; Batra SK
Adv Drug Deliv Rev; 2015 Jan; 81():16-33. PubMed ID: 25453266
[TBL] [Abstract][Full Text] [Related]
24. Role of microRNAs in gynecological pathology.
Gilabert-Estelles J; Braza-Boils A; Ramon LA; Zorio E; Medina P; Espana F; Estelles A
Curr Med Chem; 2012; 19(15):2406-13. PubMed ID: 22455593
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA profiles in neuroblastoma: Differences in risk and histology groups.
Ergin K; Aktaş S; Altun Z; Dınız G; Olgun N
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e374-e379. PubMed ID: 29115037
[TBL] [Abstract][Full Text] [Related]
26. Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs.
Das S; Bryan K; Buckley PG; Piskareva O; Bray IM; Foley N; Ryan J; Lynch J; Creevey L; Fay J; Prenter S; Koster J; van Sluis P; Versteeg R; Eggert A; Schulte JH; Schramm A; Mestdagh P; Vandesompele J; Speleman F; Stallings RL
Oncogene; 2013 Jun; 32(24):2927-36. PubMed ID: 22797059
[TBL] [Abstract][Full Text] [Related]
27. miRNA and cancer; computational and experimental approaches.
Tutar Y
Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
[TBL] [Abstract][Full Text] [Related]
28. MicroRNAs: novel biomarkers for human cancer.
Bartels CL; Tsongalis GJ
Clin Chem; 2009 Apr; 55(4):623-31. PubMed ID: 19246618
[TBL] [Abstract][Full Text] [Related]
29. miR-204 mediates post-transcriptional down-regulation of PHOX2B gene expression in neuroblastoma cells.
Bachetti T; Di Zanni E; Ravazzolo R; Ceccherini I
Biochim Biophys Acta; 2015 Aug; 1849(8):1057-65. PubMed ID: 26145533
[TBL] [Abstract][Full Text] [Related]
30. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma.
Buechner J; Tømte E; Haug BH; Henriksen JR; Løkke C; Flægstad T; Einvik C
Br J Cancer; 2011 Jul; 105(2):296-303. PubMed ID: 21654684
[TBL] [Abstract][Full Text] [Related]
31. Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs.
Haug BH; Hald ØH; Utnes P; Roth SA; Løkke C; Flægstad T; Einvik C
Anticancer Res; 2015 May; 35(5):2521-30. PubMed ID: 25964525
[TBL] [Abstract][Full Text] [Related]
32. N-myc and noncoding RNAs in neuroblastoma.
Buechner J; Einvik C
Mol Cancer Res; 2012 Oct; 10(10):1243-53. PubMed ID: 22936790
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation.
Parodi F; Carosio R; Ragusa M; Di Pietro C; Maugeri M; Barbagallo D; Sallustio F; Allemanni G; Pistillo MP; Casciano I; Forlani A; Schena FP; Purrello M; Romani M; Banelli B
Biochim Biophys Acta; 2016 Dec; 1859(12):1502-1514. PubMed ID: 27751904
[TBL] [Abstract][Full Text] [Related]
34. MicroRNAs: biogenesis, roles for carcinogenesis and as potential biomarkers for cancer diagnosis and prognosis.
Kavitha N; Vijayarathna S; Jothy SL; Oon CE; Chen Y; Kanwar JR; Sasidharan S
Asian Pac J Cancer Prev; 2014; 15(18):7489-97. PubMed ID: 25292018
[TBL] [Abstract][Full Text] [Related]
35. microRNA‑202 suppresses MYCN expression under the control of E2F1 in the neuroblastoma cell line LAN‑5.
Li YG; He JH; Yu L; Hang ZP; Li W; Shun WH; Huang GX
Mol Med Rep; 2014 Feb; 9(2):541-6. PubMed ID: 24337320
[TBL] [Abstract][Full Text] [Related]
36. microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest.
Zhao Z; Ma X; Sung D; Li M; Kosti A; Lin G; Chen Y; Pertsemlidis A; Hsiao TH; Du L
RNA Biol; 2015; 12(5):538-54. PubMed ID: 25760387
[TBL] [Abstract][Full Text] [Related]
37. MicroRNAs as prospective biomarkers, therapeutic targets and pharmaceuticals in neuroblastoma.
Andreeva N; Usman N; Druy A
Mol Biol Rep; 2023 Feb; 50(2):1895-1912. PubMed ID: 36520359
[TBL] [Abstract][Full Text] [Related]
38. Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas.
Naraparaju K; Kolla V; Zhuang T; Higashi M; Iyer R; Kolla S; Okawa ER; Blobel GA; Brodeur GM
Oncotarget; 2016 Mar; 7(13):15977-85. PubMed ID: 26895110
[TBL] [Abstract][Full Text] [Related]
39. A combined experimental and computational study on peptide nucleic acid (PNA) analogues of tumor suppressive miRNA-34a.
Piacenti V; Langella E; Autiero I; Nolan JC; Piskareva O; Adamo MFA; Saviano M; Moccia M
Bioorg Chem; 2019 Oct; 91():103165. PubMed ID: 31419642
[TBL] [Abstract][Full Text] [Related]
40. Recent trends in targeting miRNAs for cancer therapy.
Shah V; Shah J
J Pharm Pharmacol; 2020 Dec; 72(12):1732-1749. PubMed ID: 32783235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
